(Press-News.org) A unique commission that today issued major new recommendations aimed at fully understanding and reducing the global burden of heart disease in women was led by Roxana Mehran, MD, Professor of Medicine, and Population Health Science and Policy, and Director of Interventional Cardiovascular Research and Clinical Trials at the Icahn School of Medicine at Mount Sinai.
"The Lancet Women and Cardiovascular Disease Commission" developed specific, worldwide recommendations for heart disease prevention and treatment based on an unprecedented global review and analysis. The recommendations included expanding education and health programs, and research on women's heart disease. The commission's report was published on May 16 in The Lancet, and simultaneously presented at the American College of Cardiology's 70th Annual Scientific Session.
Cardiovascular disease is the leading cause of death for women around the world. There are roughly 275.2 million women diagnosed with heart disease worldwide, and 20.8 million in the United States, a majority of these cases are preventable.
The Lancet Women and Cardiovascular Disease Commission report was authored by 17 senior experts in the field from 11 countries. Their goals were to address current gaps in knowledge among physicians and patients, outline region-specific recommendations for reducing the burden of heart disease in women, and ultimately improve the outcomes of women with cardiovascular disease by 2030.
"For the first time ever, we are trying to gain a comprehensive understanding of what it may take to reduce heart disease among women worldwide. This problem has persisted unchanged for decades and this commission is a critical step toward finding solutions," says Dr. Mehran. "For example, physicians are aware that hypertension, smoking, hyperlipidemia, and diabetes are the most important evidence-based risk factors for heart disease. We now need to direct our study toward lesser-known risk factors that impact women's health. Specifically, stress, psychosocial, and economic deprivation play a pronounced but understudied role. The commission concludes that by studying these types of factors, we can better prevent, identify, and treat heart disease, reducing mortality rates and improving women's health on a global scale."
The commission's recommendations are based on an analysis of the 2019 Global Burden of Disease Study data coordinated by the Institute for Health Metrics and Evaluation - an independent global health research center at the University of Washington. Among other findings, the report highlights that women are disproportionately affected by certain risk factors for heart disease compared to men, including sex-specific factors such as preterm delivery, premature menopause, and domestic violence. Additionally, women in all stages of life are at risk of developing risk factors for heart disease, including those who had childhood obesity, and pre-eclampsia. The report points out socioeconomic factors such as education and access to care that play a significant role in the prevalence and impact of heart disease in women around the world. The review finds more attention should be directed to addressing the increasing rates of heart attack and heart disease among young women.
Based on these findings, the Commission outlined an ambitious list of ten recommendations for reducing the burden of cardiovascular disease in women over the next decade. They include educating health care providers and patients on early detection to prevent heart disease in young women; scaling up heart health programs in highly populated and underdeveloped regions; and prioritizing sex-specific research on heart disease in women and intervention strategies.
"Establishing these recommendations is an important step, but it's even more important how the ten these key messages are pragmatically implemented into concrete real-life settings. Furthermore, Mount Sinai research has also shown that in order to help reduce the global burden of women's heart disease, it's important to develop motivating heart disease prevention programs starting in early childhood and for women before and during pregnancy," says Valentin Fuster, MD, PhD, Director of Mount Sinai Heart and Physician-in-Chief of The Mount Sinai Hospital.
"These recommendations are a roadmap for combating this No. 1 killer of women around the world. It is an undertaking of massive scale and scope and will require total commitment from governments, health organizations, technology sectors, and funding agencies to prioritize this urgent need for change. It is our hope that this roadmap will be the north star for the future of women's heart health," added Dr. Mehran.
INFORMATION:
The Commission was supported financially by grants from Abbott Vascular, Abiomed, Amgen, AstraZeneca, Bristol Myers Squibb, CSL Behring, Janssen, Medtronic, Orbus Neich, Philips, and Sanofi, who had no role in study design, data collection, data analysis, data interpretation, or writing of this Commission article. The funds were used towards the planning, development, and public launch of the Commission article. None of the authors were paid for their work on the Commission.
About the Mount Sinai Health System
The Mount Sinai Health System is New York City's largest academic medical system, encompassing eight hospitals, a leading medical school, and a vast network of ambulatory practices throughout the greater New York region. Mount Sinai is a national and international source of unrivaled education, translational research and discovery, and collaborative clinical leadership ensuring that we deliver the highest quality care--from prevention to treatment of the most serious and complex human diseases. The Health System includes more than 7,200 physicians and features a robust and continually expanding network of multispecialty services, including more than 400 ambulatory practice locations throughout the five boroughs of New York City, Westchester, and Long Island. Mount Sinai Heart at The Mount Sinai Hospital is within the nation's No. 6-ranked heart center, and The Mount Sinai Hospital is ranked No. 14 on U.S. News & World Report's "Honor Roll" of the Top 20 Best Hospitals in the country and the Icahn School of Medicine as one of the Top 20 Best Medical Schools in country. Mount Sinai Health System hospitals are consistently ranked regionally by specialty and our physicians in the top 1% of all physicians nationally by U.S. News & World Report.
For more information, visit https://www.mountsinai.org or find Mount Sinai on Facebook, Twitter and YouTube.
The Lancet women and cardiovascular disease Commission outlines 10 ambitious recommendations to improve health outcomes for millions of women around the world and achieve the global targets set.
In the first-ever global report on cardiovascular disease (CVD) in women, researchers call for urgent action to improve care and prevention, fill knowledge gaps, and increase awareness to tackle the worldwide leading cause of death among women. The all female-led Commission report was published in The Lancet and presented during a plenary session at the American College of Cardiology's 70th Annual Scientific Session (ACC.21). ...
ATS 2021, New York, NY - Patients with idiopathic pulmonary fibrosis (IPF), a rare lung disease that causes shortness of breath and low oxygen levels because of lung scarring, have worse outcomes if they live in poor neighborhoods, according to research presented at the ATS 2021 International Conference.
Gillian Goobie, MD, Human Genetics, Graduate School of Public Health, University of Pittsburgh, and colleagues sought to determine how environmental and occupational factors contribute to the development and progression of IPF. People who live in areas with high neighborhood-level disadvantage, as ...
ATS 2021, New York, NY - By removing "race correction" from the interpretation of pulmonary function test (PFT) results, Black individuals were shown to have a significantly higher prevalence and severity of lung disease, according to research presented at the ATS 2021 International Conference.
Alexander Moffett, MD, clinical fellow, Division of Pulmonary, Allergy and Critical Care, University of Pennsylvania Perelman School of Medicine, and colleagues, sought to determine the real-world consequences of race correction for the interpretation of PFT results. Race correction, a standard practice in PFT interpretation that has no biological basis, results ...
NEW YORK, NY (May 16, 2021)--Brief pulses of ultrasound delivered to nerves near the kidney produced a clinically meaningful drop in blood pressure in people whose hypertension did not respond to a triple cocktail of medications, reports a new study led by researchers at Columbia University Vagelos College of Physicians and Surgeons and NewYork-Presbyterian.
In a clinical trial of the procedure, called renal denervation, daytime blood pressure after two months had dropped 8 points compared to a 3-point drop in patients who were treated with a sham procedure. Nighttime blood pressure decreased ...
Research led by scientists at Children's Cancer Institute and published this week in the international journal, Clinical Cancer Research, has found a combination of therapies that appears to be highly effective against high-risk neuroblastoma and other forms of aggressive childhood cancer.
Up to half of all cases of neuroblastoma newly diagnosed in children are 'high-risk', meaning the cancer grows aggressively and is difficult to treat. Despite receiving intensive treatment, most children with high-risk disease die within five years of diagnosis, while those who survive are often left with serious ...
ATS 2021, New York, NY - A weighted "lottery" designed to increase access to the antiviral drug remdesivir during the May-July 2020 COVID-19 surge for those most affected by the coronavirus, including members of the Black, Latinx and indigenous communities, led to more equitable distribution of the badly needed medication, according to research presented at the ATS 2021 International Conference.
At a time when supplies of COVID-19 medications were scarce, Douglas B. White, MD, MAS, vice chair and professor of critical care medicine, UPMC endowed chair for ethics in critical care medicine and director of the Program on Ethics and Decision Making in Critical Illness, University of Pittsburgh School of Medicine, and colleagues, convened ...
WINSTON-SALEM, N.C. - May 16, 2021 - Heart failure (HF) - when the heart can't pump enough blood and oxygen through the body - affects approximately 6.2 million adults in the United States and is the primary cause of hospitalization in the elderly. Unfortunately, older adults with heart failure often have poor outcomes resulting in reduced quality of life, high mortality and frequent rehospitalizations.
Despite many efforts to improve the prognosis in these patients, most previous studies testing a wide range of interventions were not successful.
Scientists from the Wake Forest, Duke University and Thomas Jefferson ...
An innovative cardiac rehabilitation intervention started earlier and more custom-tailored to the individual improved physical function, frailty, quality-of-life, and depression in hospitalized heart failure patients, compared to traditional rehabilitation programs. Supported by the National Institute on Aging (NIA), part of the National institutes of Health, these new study results were published May 16 in the New England Journal of Medicine and also presented at the American College of Cardiology's 70th Annual Scientific Session.
"Designing earlier and more personalized individual-specific approaches to heart failure rehab shows great promise for improving outcomes for this common but complex condition that is ...
The investigational drug evinacumab reduced triglycerides in patients with severe hypertriglyceridemia (sHTG) and a history of hospitalizations for acute pancreatitis in a phase 2 global study led by Mount Sinai. The fully human monoclonal antibody produced sustained reductions in triglyceride levels of up to 82 percent, depending on the patient's genotype, while also lowering the risk of recurrent acute pancreatitis. The results of the study will be presented as a late-breaking clinical trial at the American College of Cardiology (ACC) Annual Scientific Session, on May 16.
"Evinacumab has the potential to not only lower triglycerides, but the risk of acute pancreatitis, quality of life, and the risk of cardiovascular events in ...
Hamilton, ON (May 15, 2021) - A simple surgery saves patients with heart arrhythmia from often-lethal strokes, says a large international study led by McMaster University.
Researchers found that removing the left atrial appendage -- an unused, finger-like tissue that can trap blood in the heart chamber and increase the risk of clots -- cuts the risk of strokes by more than one-third in patients with atrial fibrillation.
Even better, the reduced clotting risk comes on top of any other benefits conferred by blood-thinner medications patients with this condition are usually prescribed.
"If you have atrial fibrillation and are undergoing heart surgery, the surgeon should be removing your left atrial appendage, because it is a set-up for forming clots. Our trial has shown ...
